Hi Gary,
access to one of the 2nd Gen TKIs depends on where you live. Nilotinib, as Karen has already suggested, is available through the NHS for both 2nd and 1st line therapy in England, as NICE recommended its use after the last HTA appraisal - its price is equal to standard dose imatinib. The SMC in Scotland also recommended nilotinib. So it should be easy for you to change to that TKI.
Dasatinib is currently more expensive. However, it is available in England through an application (by a doctor) to the CDF (cancer Drugs fund)-
in Scotland, Wales and N.Ireland you have to go through a different process as they do not have a CDF.
3rd generation TKIs bosutinib and ponatinib are currently available through a clinical study or compassionate use. However the good news is that bosutinib is available through the CDF in England. It is also currently going through the NICE HTA process-
(the NICE appraisal committee will publish their final decision some point in late Sept early October I think.
All TKIs have side effects but also all differ in their side effect profiles. You need to talk with your doctor about whether nilotinib would suit you and if not, which of the others might be a good choice- you should not 'put up with' imatinib side effects if they affect your quality of life.
If you are in England and your doctor is willing to fill in some forms (not complicated) and apply to the CDF then you might prefer dasatinib as an alternative given your busy working life.
BTW what has been your clinical response to imatinib? I assume your PCR results are good?
Sandy